CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 800 enrolled
Drug / intervention
cobalamin +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03071666
NCT03071666Phase 3Active

Supplementation of Vitamin B12 in Pregnancy and Postpartum on Growth and Cognitive Functioning in Early Childhood: A Randomized, Placebo Controlled Trial

Centre For International Health·interventional·Posted Mar 7, 2017·Updated Apr 27, 2026

In Brief

A Phase 3 clinical trial evaluating cobalamin and placebo for Pregnancy Related and 2 related conditions. Active but no longer recruiting, targeting 800 participants across 1 site.

Detailed Summary

Scientific basis: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only relevant source of vitamin B12 is animal-source foods and poor gut function may decrease absorption. Vitamin B12 is crucial for normal cell division and differentiation, and necessary for the development and myelination of the central nervous system. Deficiency is also associated with impaired fetal and infant growth. In the proposed study we will measure the effect of daily oral vitamin B12 supplementation to pregnant women on neurodevelopment and growth of their children. We also aim to measure the impact of B12 supplementation on several other outcomes. Study design: Individually randomized double-blind placebo controlled trial in pregnant South Asian women at risk of poor vitamin B12 status. Participants will be randomized in a 1:1 ratio. Study participants and site: 800 pregnant women from early pregnancy. Women will be enrolled as early as possible, but no later than in week 15 of pregnancy. Intervention: Daily administration of 50 µg of vitamin B12 from early pregnancy until 6 months after birth. Comparator: Placebo, identical to the vitamin B12 supplements. Outcomes: Primary: (i) neurodevelopment in children measured at 6 and 12 months of age (ii) growth in children measured by weight and length at 12 months. Secondary: (i) neurodevelopment and cognitive functioning in children at 24 months (ii) gestational age at birth, (iii) fetal and infant growth measured by weight and length at birth, after 1 month and then at 3, 6, 9, and 24 months, (iv) hemoglobin concentration in children and mothers. Relevance for programs and public health: The results from this study can suggest new dietary guidelines for South Asian women that again can lead to improved pregnancy outcomes and neurodevelopment and cognitive functioning in South Asian children.

Study Details

Timeline

Phase 3Active
20172018201920202021202220232024202520262027202820292030
First PostedMar 7, 2017
Enrollment StartMar 27, 2017
Primary CompletionJun 28, 2022
Study CompletionDec 31, 2029
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 9.3 years ago

Interventions

cobalamindietary

Vitamin supplment tablet containing 50µg cobalamin

placebodietary

A tablet identical to the vitamin supplement but containing no vitamin B12